JPET #67793

INTRODUCTION
Thalidomide (α-phthalimidoglutarimide, Thal), despite its teratogenicity (McBride, 1961; Lenz, 1962) , is attracting increasing clinical interest, initially as an anti-inflammatory agent (Sheskin, 1965; Zwingenberger and Wnendt, 1996; Calabrese and Fleischer, 2000) and more recently for the treatment of malignancies, particularly of multiple myeloma (Singhal et al., 1999; Eisen, 2000) . Differences in metabolism among different species represent an important feature of its pharmacology. It has been suggested that Thal exerts its teratogenicity through an active metabolite, which is produced by human and rabbit liver microsomes preparation but not by mouse liver microsomes (Gordon et al., 1981) . Following in vivo administration, Thal is both hydrolyzed chemically to a series of acid derivatives and hydroxylated by liver enzymes. In a previous study (Chung et al., Submitted) we showed that the plasma half-life of Thal in mice was much shorter than that in patients with multiple myeloma, with New Zealand White rabbits showing an intermediate half-life. We also showed that hydroxylated metabolites were not detected in multiple myeloma patients but were found in C57/Bl/6 mice and rabbits, suggesting that relative rates of Thal hydroxylation in different species could account for the differences in plasma pharmacokinetics, hence the differences in biological sensitivity. In this communication we have addressed the question of whether these species differences are reflected in the in vitro activity of liver microsomal enzymes.
There have been a number of other studies on the in vitro metabolism of Thal in different species. Ando and co-workers compared the ability of liver microsomes from five different species to form 5-hydroxythalidomide (5-OH Thal) and cis-5'-OH Thal and found that human JPET #67793 5 microsomes had the lowest activity (Ando et al., 2002a) . The formation of 5,6-dihydroxythalidomide was also reported, with CYP2C19 identified as responsible for the hydroxylation of Thal in humans. Another study (Eriksson et al., 1998) has compared the formation of hydroxylated metabolites in vitro using human S9 liver fractions and in vivo in healthy human volunteers: both 5-OH Thal and cis-5'-OH Thal were formed in vitro but only cis-5'-OH Thal was detected in vivo. However, Teo and co-workers did not detect any metabolites after incubating Thal with human liver microsomes or in the plasma of patients with Hansen's disease, although trace amounts of 5-OH Thal were detected in urine (Teo et al., 2000) .
We have taken advantage of progress in the chemical synthesis of Thal metabolites, together with the development of high performance liquid chromatography (HPLC) and LC-MS technologies, to determine the rate of 5-OH Thal formation in liver microsomes of mice, rabbits and humans, as well as to characterize all the major metabolites formed in vitro in order to compare them with those formed in vivo.
MATERIALS AND METHODS
Materials. Thal was kindly provided by Dr George Muller, Celgene Corporation (Warren, NJ).
Phthaloylglutamic acid, TCA and NADPH were from Sigma-Aldrich (St. Louis, MO), acetonitrile from BDH Laboratory Supplies (Poole, UK) and glacial acetic acid from Panreac Quimica SA (Barcelona, Spain). Phthaloylisoglutamine, phthaloylglutamine, glutamic acid imide and 5-hydroxy-N-(o-JPET #67793 6 carboxybenzoyl)glutamic acid imide were synthesized as previously described (Lu et al., 2003) and their structures were confirmed using 400 MHz 1 H nuclear magnetic resonance spectroscopy and mass spectrometry. 5,6-Dihydroxythalidomide was prepared by reaction of 5,6-dimethoxyphthalic anhydride (Barfield et al., 1975) Pooled C57/Bl/6 mouse livers and livers from New Zealand White rabbit and human donors were rinsed in ice-cold phosphate buffer (pH 7.4) and blotted dry. Liver weights were recorded.
Livers were then homogenized in 67 mM phosphate buffer containing 1.15% KCl (volume of buffer was 3 times weight of liver). The homogenate was then centrifuged at 10,000 x g for 20 min, and the supernatant was removed and centrifuged at 100,000 x g for 1 h. The supernatant was again removed and the remaining microsomal pellets were rinsed with phosphate buffer. The rinsed pellets were re-suspended in a small volume of phosphate buffer and stored at -80ºC until JPET #67793 7 analysis. The protein content of microsomes of all three species was determined using bicinchoninic acid assay (Smith et al., 1985) .
Microsomal Incubation and Sample Preparation for HPLC and LC-MS.
In the preliminary control experiments, the degradation of 400 µ M Thal was <10% in phosphate buffer at 37ºC. The rate of Thal hydroxylation was linear with respect to microsomal protein concentration (0.4 -2 mg/ml) and time (10 -30 min) in mouse and rabbit hepatic microsomes and linear between 0.6 -2 mg/ml and 40 -60 min in the presence of human liver microsomes.
Incubations were carried out in a shaking water bath at 37ºC for 30 min for mouse and rabbit microsomes and 60 min for human microsomes. The reaction mixture consisted of 67 mM phosphate buffer (pH 7.4), 4 mM NADPH, Thal (6.25 -600 µ M) and 2 mg/ml microsomes in a final volume of 300 µ l. Thal was dissolved in DMSO, then diluted in phosphate buffer (final concentration of DMSO was <0.2%). After a 5-min pre-incubation, the reaction was initiated by addition of hepatic microsomes. Boiled microsomes were added to the control incubations. The reaction was terminated by addition of 300 µ l 10% TCA containing phenacetin as an internal standard and was then vortexed and centrifuged (3,000 x g) for 10 min to remove precipitated protein (Torano et al., 1999) . The supernatants were then processed by solid phase extraction as described previously (Lu et al., 2003) and the dry residues were reconstituted in 300 µ l of mobile phase. Reconstituted samples were analyzed for 5-OH Thal concentration (200 µ l each) using HPLC and metabolite identification (100 µ l each) determined by LC-MS immediately afterwards.
This article has not been copyedited and formatted. The final version may differ from this version. Phenacetin, Thal and 5-OH Thal were detected at ultraviolet wavelengths of 220 and 248 nm.
The retention times of 5-OH Thal and phenacetin were 20.1 and 22.8 min, respectively. Data acquisition and integration was achieved using Breeze Software (Milford, CA, USA). A calibration curve of 5-OH Thal in phosphate buffer was prepared fresh for each HPLC run. To construct the calibration curve, the peak-area ratios relative to the internal standard were plotted against 5-OH Thal concentrations and the best-fit straight line was obtained by linear regression analysis. The range of calibration curve of 5-OH Thal was 0.1-25 µ M (r added were stored at -80 °C. These were included in each analysis and were found to be stable over a period of 14 days and within 3% of the validated value respectively. Reconstituted samples (100 µl each in duplicate) were injected onto HPLC and 5-OH Thal concentrations were determined using calibration curve described above. The 5-OH Thal concentrations were used to calculate the rate of formation. Michaelis-Menten models were used to describe the in vitro enzyme kinetics, and the kinetic parameters were determined by Prism 3.0 program (Graphpad Software Co., CA).
RESULTS
Metabolites Formed following Incubation of Thal with Hepatic Microsomes.
Following incubation of Thal (400 µ M) with rabbit and mouse liver microsomes (0.4 -2 mg/ml) for 60 min in the presence of NADPH (4 mM), eleven peaks (1-11), in addition to Thal (Table 1; Fig. 1B, 1C) were resolved. In contrast, only seven peaks (1, 2, 5-7 & 10-11) were detected using human (HL18) liver microsomes (Fig. 1A ). Four peaks (1, 2, 5 & 6) in the control incubations (with boiled microsomes) were identified by UV and mass spectral analysis and comparison with authentic standards as products of hydrolysis ( Fig. 1 & 2) . Four of the remaining seven peaks formed by mouse and rabbit liver microsomes were identified as the previously reported hydroxyl derivatives (Lu et al., 2003; Chung et al., 2004) , namely 5-OH Thal and 5'-hydroxy-N-(o-carboxybenzoyl)glutamic acid imide plus cis-and trans-5'-OH Thal (4, 7, 10 and 11; Fig. 1B,C). The remaining three peaks (3, 8 and 9) were products of further hydroxylation reactions as they had an identical molecular mass that was 16 a.m.u. higher than 5-OH Thal or 5'-OH Thal and were therefore assigned as dihydroxylated metabolites. None of these metabolites had This article has not been copyedited and formatted. The final version may differ from this version. (7) and trans-5'-OH Thal (10) (Fig.   1A ). However, microsomes from HL5 failed to produce any detectable hydroxylation metabolites.
A comparison of the relative formation of hydroxylated metabolites by hepatic microsomes in the different species indicates that metabolic rate via hydroxylation is mouse > rabbit > human (Table 2 ). In particular, the relative abundance of each of the hydroxylated metabolite peaks produced by HL18 microsomes was much lower than the corresponding peak formed by mouse or rabbit liver microsomes (Table 2) . Similarly, the relative amount of hydroxylated metabolites was higher in the presence of mouse liver microsomes compared with rabbit liver microsomes, with the exception of Peak 3.
The relative amount of hydrolysis products formed in microsomes from all three species did not differ significantly from the amount in control samples regardless of microsomal concentrations, with the exception of phthaloylisoglutamine (Peak 5) and N-(ocarboxybenzoyl)isoglutamine (Peak 2) in rabbit microsomal solutions ( Fig. 1 and 2 ; Table 3 ). Another finding in accordance with the above finding is that incubating rabbit and mouse microsome with Thal at 6.25 µM did not show difference in phthaloylisoglutamine formation, but when Thal concentrations were raised to 12.5 µM and above, rabbit liver microsome formed more phthaloylisoglutamine than mice.
The relative percentages of metabolite formation were obtained by comparing the peak areas of metabolites detected by UV with the sum of peak areas of all the metabolites and thalidomide (Fig. 2) . A comparison of the relative total formation of hydrolysis products and hydroxylated metabolites in microsomes from the three species indicates that rabbit has the highest overall metabolic clearance of Thal (25.7%) mainly due to enzymatic hydrolysis (Table   4 ). In human and mouse liver microsomes, the formation of hydrolysis products was lower (7.7-7.9%) and due solely to non-enzymatic hydrolysis (Table 4 ). In contrast, metabolic clearance of Thal via hydroxylation was negligible in human liver microsomes and highest in mouse microsomes (6.1%). We used conditions optimized for 5-OH Thal formation (higher microsomal protein concentration and shorter incubation time) to calculate the kinetic parameters because it appeared to be the major route of metabolism detected in vivo (Lu et al., 2003; Chung et al., Submitted) . carboxybenzoyl)glutamic acid imide. In addition, three metabolites (3, 8 and 9), with masses consistent with dihydroxylation have been detected. These were not observed in vivo, and it is possible that their sources, mono-hydroxylated metabolites, are rapidly cleared by glucuronidation, as in the case of 5-OH Thal (Lu et al., 2003) . In vitro formation of 5-OH Thal and cis-5'-OH Thal, as well as of 5,6-dihydroxythalidomide and several unidentified metabolites, has been reported (Ando et al., 2002a) . However, in our study none of metabolites (3, 8 and 9) corresponded to authentic 5,6-dihydroxythalidomide. Thal-5-O-glucuronide, which has been detected in our in vivo study was also not detected possibly due to the lack of uridine diphosphate glucuronide as a co-factor in the in vitro experiment setting.
Rate of 5-OH
However, as products of further hydroxylation of cis-, trans-5'-OH
Non-enzymatic hydrolysis of Thal was observed in these studies confirming previous results from other groups in a number of species including rats, humans and rabbits (Faigle, 1962; Keberle et al., 1965; Schumacher et al., 1965; Williams et al., 1965) . In addition, we have found evidence of significant enzymatic hydrolysis of Thal to phthaloylisoglutamine in rabbit hepatic microsomes. This confirms an earlier report (Schumacher et al., 1968) indicating that the rate of hydrolysis of Thal was higher in rabbit liver than in rat liver, although the specific hydrolysis pathway from Thal to phthaloylisoglutamine was not identified. Since no differences in the relative amounts of phthaloylisoglutamine in the plasma of mice and rabbits following administration of Thal (2 mg/kg p.o.) were observed (Chung et al., Submitted) , enzymatic hydrolysis would be expected to occur only at the high Thal concentrations used in in vitro experiments (≥ 12.5 µM) and not at plasma concentrations (C max < 2.2 µ M) that are observed in vivo (Chung et al., Submitted) . Thalidomide is mainly excreted in the form of metabolites as shown by that less than 1% of the administered dose is excreted unchanged in urine in many species . Total metabolic clearance of Thal in vitro via both hydrolysis (enzymatic and non-enzymatic) and hydroxylation was greatest in the rabbit and negligible in human liver microsomes. However, since enzymatic hydrolysis of Thal in the rabbit may not occur at in vivo concentrations, clearance via hydroxylation may be more important.
Although hydroxylated metabolites were measurable in human microsomal incubations with donor liver HL18, no metabolism of Thal was observed with another human liver donor HL5. This is in agreement with previous reports (Ando et al., 2002a) where of two human livers, one produced metabolites at or below the limit of quantification and the other source had very low rate of metabolite formation. Ando et al., (2002a) indicated that this was related to the relative expression of CYP2C19, however, pooled human liver microsomes were also very poor metabolizers of Thal. Of the two livers used in this study, one HL5 was homozygous wild type (*1/*1) for CYP2C19 and the other liver HL18 was a heterozygote for the mutant allele (*1/*2).
Although, in vitro studies with purified CYP2C19 indicated that this enzyme is involved in the hydroxylation of Thal, more recent in vivo studies (Ando et al., 2002b) have indicated that some patients with an extensive metabolizer genotype do not hydroxylate Thal to any significant extent. The role of CYP2C19 in the metabolism of Thal requires further study, but importantly, regardless of the CYP isozyme(s) involved, the overall rate of metabolism of Thal is negligible in human liver in comparison to mouse and rabbit.
In conclusion, the results support previous reports of low in vitro metabolic clearance of Thal in humans (Ando et al., 2002a) metabolites are not detectable in patients with multiple myeloma (Lu et al., 2003; Chung et al., Submitted) or with Hansen's disease (Teo et al., 2000) . Hydroxylated metabolites can be detected in vitro but only at concentrations of Thal (200-600 µ M) that are well above the highest plasma concentrations of Thal (50 µ M) that have reported in human studies (Figg et al., 1999) .
These results suggest that Thal is unlikely to interact with other drugs extensively metabolized by human CYP system (Trapnell et al., 1998; Scheffler et al., 1999; Teo et al., 2000) , which makes it a good candidate for combined chemotherapy. The data also strongly suggest that hydroxylated metabolites are unlikely to be involved in the mechanism of action of Thal in humans, and that the parent compound and/or its hydrolysis product(s) are involved in its action.
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